Climb Bio Income Before Tax Over Time
| CLYM Stock | 3.15 0.11 3.37% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Climb Bio Performance and Climb Bio Correlation. Climb |
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Income Before Tax Analysis
Compare Climb Bio and related stocks such as Vincerx Pharma, Viracta Therapeutics, and Dogwood Therapeutics, Income Before Tax Over Time
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VINC | (45 K) | (45 K) | (45 K) | (45 K) | (45 K) | (45 K) | (45 K) | (45 K) | (45 K) | (45 K) | (10.7 M) | (39.3 M) | (65.4 M) | (40.2 M) | (42.2 M) |
| VIRX | (26.8 M) | (20.1 M) | (44 M) | (34.6 M) | (43 M) | (36.7 M) | (38 M) | (35.5 M) | (26.6 M) | (23.3 M) | (19 M) | (114.8 M) | (49.2 M) | (51.1 M) | (53.6 M) |
| DWTX | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (16 M) | (12.2 M) | (5.3 M) | (5.6 M) |
| VKTX | (146.2 K) | (146.2 K) | (146.2 K) | (146.2 K) | (21.9 M) | (23.4 M) | (14.7 M) | (20.6 M) | (22.1 M) | (25.8 M) | (39.5 M) | (55 M) | (68.9 M) | (85.9 M) | (81.6 M) |
| DYAI | (6.1 M) | 1.4 M | 1.4 M | (428.1 K) | (6 M) | (1.5 M) | (3.4 M) | (2.2 M) | (6.7 M) | (8.3 M) | (9.3 M) | (13.1 M) | (9.7 M) | (6.8 M) | (7.1 M) |
| VNDA | (9.5 M) | (10.2 M) | (27.7 M) | (20.3 M) | 20.2 M | (39.9 M) | (17.9 M) | (15.4 M) | 25.3 M | 29 M | 31.7 M | 42.4 M | 11.3 M | 6.3 M | 6.7 M |
| KTTAW | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (2.2 M) | (13.9 M) | (15.5 M) | (14.7 M) |
| VRDN | (5.6 M) | (5.6 M) | (5.6 M) | (2.2 M) | (7.9 M) | (11.3 M) | (12.7 M) | (26.5 M) | (32.7 M) | (41.9 M) | (110.7 M) | (79.4 M) | (129.9 M) | (237.7 M) | (225.8 M) |
| CDTTW | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (4.9 M) | (535 K) | (561.8 K) |
| VRTX | (4.8 M) | 60.4 M | (12.4 M) | (976.1 M) | (734.9 M) | (559.6 M) | (67.4 M) | (15.7 M) | 600.2 M | 1.4 B | 3.1 B | 2.7 B | 4.2 B | 4.4 B | 4.6 B |
Climb Bio and related stocks such as Vincerx Pharma, Viracta Therapeutics, and Dogwood Therapeutics, Income Before Tax description
Income Before Tax which can also be referred as pre-tax income is reported on Climb Bio income statement and is an important metric when analyzing Climb Bio profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.My Equities
My Current Equities and Potential Positions
| Climb Bio | CLYM |
Specialization | Healthcare, Biotechnology |
| Location | Washington; U.S.A |
| Exchange | NASDAQ Exchange |
null 3.15
Check out Climb Bio Performance and Climb Bio Correlation. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Climb Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.